Analysts expect Tandem Diabetes Care, Inc. (NASDAQ:TNDM) to report sales of $172.80 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Tandem Diabetes Care’s earnings, with estimates ranging from $172.40 million to $174.00 million. Tandem Diabetes Care reported sales of $123.60 million in the same quarter last year, which indicates a positive year over year growth rate of 39.8%. The company is expected to report its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Tandem Diabetes Care will report full-year sales of $681.09 million for the current year, with estimates ranging from $676.30 million to $684.70 million. For the next financial year, analysts expect that the firm will report sales of $792.81 million, with estimates ranging from $762.90 million to $830.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Wednesday, August 4th. The medical device company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.14. Tandem Diabetes Care had a net margin of 1.08% and a return on equity of 3.68%. The company had revenue of $172.14 million for the quarter, compared to the consensus estimate of $143.36 million. During the same quarter in the prior year, the company earned ($0.45) EPS. Tandem Diabetes Care’s quarterly revenue was up 57.6% on a year-over-year basis.
NASDAQ:TNDM traded down $2.62 during midday trading on Monday, hitting $121.15. The company’s stock had a trading volume of 571,344 shares, compared to its average volume of 713,678. Tandem Diabetes Care has a fifty-two week low of $76.19 and a fifty-two week high of $130.73. The firm’s 50 day moving average is $112.85 and its 200-day moving average is $97.92. The company has a debt-to-equity ratio of 0.81, a current ratio of 6.42 and a quick ratio of 5.81. The firm has a market cap of $7.64 billion, a P/E ratio of 2,423.48 and a beta of 0.28.
In other news, SVP James Leal sold 1,666 shares of Tandem Diabetes Care stock in a transaction on Tuesday, July 27th. The stock was sold at an average price of $102.25, for a total transaction of $170,348.50. Following the transaction, the senior vice president now owns 5,262 shares in the company, valued at approximately $538,039.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Leigh Vosseller sold 10,000 shares of Tandem Diabetes Care stock in a transaction on Monday, September 13th. The stock was sold at an average price of $120.75, for a total value of $1,207,500.00. Following the transaction, the chief financial officer now owns 16,145 shares in the company, valued at approximately $1,949,508.75. The disclosure for this sale can be found here. Insiders sold a total of 97,287 shares of company stock worth $11,225,503 in the last 90 days. 4.80% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of TNDM. Vanguard Group Inc. increased its position in shares of Tandem Diabetes Care by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 5,604,505 shares of the medical device company’s stock worth $545,879,000 after purchasing an additional 144,143 shares during the last quarter. Jackson Square Partners LLC increased its position in shares of Tandem Diabetes Care by 16.3% during the 1st quarter. Jackson Square Partners LLC now owns 3,705,812 shares of the medical device company’s stock worth $327,037,000 after purchasing an additional 518,825 shares during the last quarter. BlackRock Inc. increased its position in shares of Tandem Diabetes Care by 1.0% during the 2nd quarter. BlackRock Inc. now owns 3,522,962 shares of the medical device company’s stock worth $343,136,000 after purchasing an additional 33,741 shares during the last quarter. Credit Suisse AG increased its position in shares of Tandem Diabetes Care by 44.2% during the 1st quarter. Credit Suisse AG now owns 2,027,597 shares of the medical device company’s stock worth $178,935,000 after purchasing an additional 621,872 shares during the last quarter. Finally, Champlain Investment Partners LLC increased its position in shares of Tandem Diabetes Care by 15.2% during the 2nd quarter. Champlain Investment Partners LLC now owns 1,546,570 shares of the medical device company’s stock worth $150,636,000 after purchasing an additional 204,410 shares during the last quarter. Institutional investors and hedge funds own 93.19% of the company’s stock.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Further Reading: Terms to Better Understand Call Options
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.